Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons

Brain Research

Volumn 1394, Issue , 2011, Pages 24-32

  Reynolds, K B ^a,b   MacGillivray, L ^a,b   Zettler, M ^a,b   Rosebush, P I ^b   Mazurek, M F ^a,b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Dopamine transporter; GBR; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

CLOZAPINE; DOPAMINE TRANSPORTER; DRINKING WATER; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; VANOXERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CELL COUNT; CELL SIZE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; MALE; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA; TOPOGRAPHY; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 79956270999     PISSN: 00068993     EISSN: 00068993     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.03.003     Document Type: Article

References (40)

1. Abercrombie, M., 1946. Estimation of nuclear population from microtome sections. Anat. Rec. 94, 239-247.
2. Andreassen, O.A., Ferrante, R.J., Aamo, T.O., Beal, M.F., Jorgensen, H.A., 2003. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122, 717-725. (Pubitemid 37410293)
3. Balijepalli, S., Boyd, M.R., Ravindranath, V., 1999. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 38, 567-577. (Pubitemid 29088234)
4. Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov, R.R., Caron, M.G., 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273. (Pubitemid 41032989)
5. Behl, C., Lezoulac'h, F., Widmann, M., Rupprecht, R., Holsboer, F., 1996. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res. 717, 193-195.
6. Ben-Shachar, D., Zuk, R., Gazawi, H., Ljubuncic, P., 2004. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 67, 1965-1974.
7. Blanchard, V., Raisman-Vozari, R., Vyas, S., Michel, P.P., Javoy-Agid, F., Uhl, G., Agid, Y., 1994. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res. Mol. Brain Res. 22, 29-38.
8. Bolan, E.A., Kivell, B., Jaligam, V., Oz, M., Jayanthi, L.D., Han, Y., Sen, N., Urizar, E., Gomes, I., Devi, L.A., Ramamoorthy, S., Javitch, J.A., Zapata, A., Shippenberg, T.S., 2007. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71, 1222-1232.
9. Brami-Cherrier, K., Valjent, E., Garcia, M., Pages, C., Hipskind, R.A., Caboche, J., 2002. Dopamine induces a PI3-kinase-independent activation of akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci. 22, 8911-8921. (Pubitemid 35379061)
10. Burkhardt, C., Kelly, J.P., Lim, Y.H., Filley, C.M., Parker Jr., W.D., 1993. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33, 512-517.
11. Ciliax, B.J., Heilman, C., Demchyshyn, L.L., Pristupa, Z.B., Ince, E., Hersch, S.M., Niznik, H.B., Levey, A.I., 1995. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714-1723.
12. Fasulo, W.H., Hemby, S.E., 2003. Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J. Neurochem. 87, 205-219. (Pubitemid 37210654)
13. Fitzgerald, L.W., Deutch, A.Y., Gasic, G., Heinemann, S.F., Nestler, E.J., 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15, 2453-2461.
14. Forno, L.S., 1996. Neuropathology of parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272.
15. Freed, C., Revay, R., Vaughan, R.A., Kriek, E., Grant, S., Uhl, G.R., Kuhar, M.J., 1995. Dopamine transporter immunoreactivity in rat brain. J. Comp. Neurol. 359, 340-349.
16. German, D.C., Dubach, M., Askari, S., Speciale, S.G., Bowden, D.M., 1988. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
17. Hakansson, K., Pozzi, L., Usiello, A., Haycock, J., Borrelli, E., Fisone, G., 2004. Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur. J. Neurosci. 20, 1108-1112.
18. Hornykiewicz, O., Kish, S.J., 1987. Biochemical pathophysiology of parkinson's disease. Adv. Neurol. 45, 19-34.
19. Jackson-Lewis, V., Przedborski, S., 1994. Neurolepticmedications inhibit complex I of the electron transport chain. Ann. Neurol. 35, 244-245.
20. Levinson, A.J., Garside, S., Rosebush, P.I., Mazurek, M.F., 1998. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84, 201-211. (Pubitemid 28081537)
21. Maurer, I., Moller, H.J., 1997. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 174, 255-259.
22. Mazurek, M.F., Savedia, S.M., Bobba, R.S., Garside, S., Rosebush, P.I., 1998. Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. J. Neurol. Neurosurg. Psychiatry 64, 799-801.
23. Mazurek, M.F., Rosebush, P.I., 1996. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am. J. Psychiatry 153, 708-710. (Pubitemid 26133627)
24. Mizukawa, K., Sora, Y.H., Ogawa, N., 1990. Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP)-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 67, 307-320.
25. Pall, H.S., Williams, A.C., Blake, D.R., Lunec, J., 1987. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2, 596-599. (Pubitemid 17131366)
26. Paxinos, G., Watson, C., 2006. The rat brain in stereotaxic coordinates. Academic Press.
27. Polydoro, M., Schroder, N., Lima, M.N., Caldana, F., Laranja, D.C., Bromberg, E., Roesler, R., Quevedo, J., Moreira, J.C., Dal-Pizzol, F., 2004. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol. Biochem. Behav. 78, 751-756.
28. Post, A., Holsboer, F., Behl, C., 1998. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J. Neurosci. 18, 8236-8246. (Pubitemid 28465001)
29. Revay, R., Vaughan, R., Grant, S., Kuhar, M.J., 1996. Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Synapse 22, 93-99. (Pubitemid 26041227)
30. Rosebush, P.I., Mazurek, M.F., 1999a. The neurologic side effects of risperidone. Essent. Psychopharmacol. 3, 43-63.
31. Rosebush, P.I., Mazurek, M.F., 1999b. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52, 782-785. (Pubitemid 29120185)
32. Rosebush, P.I., Mazurek, M.F., 1995. Complicating factors in the analysis of acute drug-induced akathisia. Arch. Gen. Psychiatry 52, 878-880.
33. Rupniak, N.M., Mann, S., Hall, M.D., Fleminger, S., Kilpatrick, G., Jenner, P., Marsden, C.D., 1984. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology (Berl) 84, 503-511. (Pubitemid 15179669)
34. Sagara, Y., 1998. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71, 1002-1012. (Pubitemid 28390254)
35. Schneider, J.S., Yuwiler, A., Markham, C.H., 1987. Selective loss of subpopulations of ventralmesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411, 144-150. (Pubitemid 17084779)
36. See, R.E., Ellison, G., 1990. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur. J. Pharmacol. 181, 175-186.
37. Titeler, M., Seeman, P., 1980. Radioreceptor labeling of pre- and postsynaptic dopamine receptors. Adv. Biochem. Psychopharmacol. 24, 159-165.
38. Ueda, Y., Yokoyama, H., Nakajima, A., Ohya-Nishiguchi, H., Kamada, H., 2000. In vivo electron spin resonance spectroscopy on signal decay of intrastriatal nitroxide radical after acute administration of haloperidol in rats. Brain Res. Bull. 51, 313-317.
39. Volavka, J., Cooper, T., Czobor, P., Bitter, I., Meisner, M., Laska, E., Gastanaga, P., Krakowski, M., Chou, J.C., Crowner, M., 1992. Haloperidol blood levels and clinical effects. Arch. Gen. Psychiatry 49, 354-361.
40. Yokoyama, H., Kasai, N., Ueda, Y., Niwa, R., Konaka, R., Mori, N., Tsuchihashi, N., Matsue, T., Ohya-Nishiguchi, H., Kamada, H., 1998. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic. Biol. Med. 24, 1056-1060.